ArticleThorax2018
Symptoms at lung cancer diagnosis are associated with major differences in prognosis.
Article in Thorax, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- A comprehensive analysis of lung cancer status changes over 10 years: results of Moroccan cohort.BJC reports · 2026Article
- Association of symptoms at diagnosis with prognosis in patients with surgically treated stage I non-small cell lung cancer: a retrospective cohort analysis of a prospectively maintained registry.Translational lung cancer research · 2026Article
- Predictors of prolonged hospital stay in patients with lung cancer undergoing sublobar resection.Translational lung cancer research · 2026Article
- Diagnostic pathways for lung cancer patients in Denmark: General practice events, first referral and stage at diagnosis.Acta oncologica (Stockholm, Sweden) · 2026Article
- Characteristics, treatment, and outcome of recurrent gastro-oesophageal adeno-carcinoma after perioperative chemotherapy and radical resection.Acta oncologica (Stockholm, Sweden) · 2026Article
- Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future.International journal of molecular sciences · 2025Review
- Outcomes and Prognostic Factors of Extensive Stage Small Cell Lung Cancer: A Retrospective Study.South Asian journal of cancer · 2025Article
- Clinicopathological characteristics and prognosis of non-small cell lung cancer in Algeria: a single-center retrospective study.BMC cancer · 2024Article
- Efficient lung cancer detection using computational intelligence and ensemble learning.PloS one · 2024Article
- A population-based study on social inequality and barriers to healthcare-seeking with lung cancer symptoms.NPJ primary care respiratory medicine · 2022Article
- Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy.Asia-Pacific journal of oncology nursing · 2022Article
- Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.Translational lung cancer research · 2021Article
- Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival.Translational lung cancer research · 2021Review
- Knockdown of LncRNA LINC00958 Inhibits the Proliferation and Migration of NSCLC Cells by MiR-204-3p/KIF2A Axis.Cell transplantationArticle
- Worse Prognosis in the Symptomatic Patients With Lung Cancer - Czech Multicentric Study.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a cohort study of survival of patients with lung cancer presenting to a single multidisciplinary team between 1997 and 2011, according to symptoms at presentation. The overall median survival of the 3800 lung cases was 183 days (95% CI 171 to 195). There was a statistically significant difference in survival between the 12 symptom groups identified both without and with adjustment for the prognostic variables of age, gender and histology (P<0.001). Compared with the cough-alone symptom group, the risks of dying or HRs were significantly higher for the groups presenting with breathlessness (HR 1.86, 95% CI 1.54 to 2.24, n=359), systemic symptoms (HR 1.91, 95% CI 1.48 to 2.45, n=95), weight loss (HR 2.46, 95% CI 1.90 to 3.18, n=106), chest pain (HR 1.96, 95% CI 1.56 to 2.45, n=159), cough with breathlessness (HR 1.59 95% CI 1.28 to 1.98, n=177), neurological symptoms (HR 3.07, 95% CI 2.45 to 3.84, n=155) and other symptom combinations (HR 2.05, 95% CI 1.75 to 2.40, n=1963). Cough may deserve particular prominence in public health campaigns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.